Mark Heise

5.0k total citations · 1 hit paper
26 papers, 3.6k citations indexed

About

Mark Heise is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Mark Heise has authored 26 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Surgery. Recurrent topics in Mark Heise's work include Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (11 papers) and Peroxisome Proliferator-Activated Receptors (9 papers). Mark Heise is often cited by papers focused on Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (11 papers) and Peroxisome Proliferator-Activated Receptors (9 papers). Mark Heise collaborates with scholars based in United States, United Kingdom and Canada. Mark Heise's co-authors include Giancarlo Viberti, Steven E. Kahn, Bernard Zinman, Steven M. Haffner, Rury R. Holman, William H. Herman, John M. Lachin, Barbara G. Kravitz, Mark O’Neill and Nigel C. Jones and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Diabetes Care.

In The Last Decade

Mark Heise

24 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006 2.2k citations Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Heise United States	13	2.6k	2.0k	936	346	333	26	3.6k
Barbara G. Kravitz United States	15	2.4k 0.9×	1.9k 1.0×	906 1.0×	389 1.1×	289 0.9×	23	3.6k
Mark O’Neill United Kingdom	9	2.0k 0.8×	1.3k 0.7×	807 0.9×	300 0.9×	302 0.9×	13	2.6k
Riccardo Candido Italy	28	1.3k 0.5×	1.1k 0.6×	525 0.6×	363 1.0×	240 0.7×	120	3.5k
James F. List United States	32	6.7k 2.6×	3.5k 1.8×	3.3k 3.6×	327 0.9×	274 0.8×	46	7.3k
Itamar Raz United States	9	4.0k 1.6×	1.6k 0.8×	1.6k 1.7×	266 0.8×	105 0.3×	9	4.7k
Martin Ridderstråle Sweden	29	1.4k 0.5×	1.4k 0.7×	615 0.7×	1.1k 3.2×	360 1.1×	84	3.7k
Akihiro Inazu Japan	38	2.1k 0.8×	1.0k 0.5×	3.1k 3.4×	299 0.9×	393 1.2×	136	4.9k
Jeffrey M. Hoeg United States	28	735 0.3×	647 0.3×	1.4k 1.5×	206 0.6×	232 0.7×	68	3.0k
Søren S. Lund Germany	22	1.5k 0.6×	659 0.3×	635 0.7×	245 0.7×	100 0.3×	50	1.9k
Steven G. Terra United States	27	3.4k 1.3×	1.9k 1.0×	1.2k 1.3×	260 0.8×	76 0.2×	78	4.2k

Countries citing papers authored by Mark Heise

Since Specialization

Citations

This map shows the geographic impact of Mark Heise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Heise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Heise more than expected).

Fields of papers citing papers by Mark Heise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Heise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Heise. The network helps show where Mark Heise may publish in the future.

Co-authorship network of co-authors of Mark Heise

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Heise. A scholar is included among the top collaborators of Mark Heise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Heise. Mark Heise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abraham, Sonya, Davide Carone, Orell Mielke, et al.. (2025). Automatically quantified follow-up imaging biomarkers predict clinical outcomes after acute ischemic stroke. Frontiers in Neurology. 16. 1483138–1483138.

Gibson, C. Michael, Serge Korjian, Gerald Chi, et al.. (2022). CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial. Journal of Cardiovascular Pharmacology and Therapeutics. 27. 2214679523–2214679523. 11 indexed citations

Chi, Gerald, Jane Lee, Clara Fitzgerald, et al.. (2021). EARLY AND LATE RECURRENT CARDIOVASCULAR RISK IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME - META-ANALYSIS AND IMPLICATIONS IN TRIAL DESIGN. Journal of the American College of Cardiology. 77(18). 137–137. 1 indexed citations

Powles, Thomas, Sergio Bracarda, Chen Mei, et al.. (2015). Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. European Journal of Cancer. 51(10). 1293–1302. 45 indexed citations

Rey, Jean‐Marc, Oliver Schreiner, Mark Heise, et al.. (2011). Acute Renal Failure and Liver Dysfunction after Subcutaneous Injection of 3-sn-Phosphatidylcholine (Lipostabil®) - Case Report. Zeitschrift für Gastroenterologie. 49(3). 340–343. 6 indexed citations

Cobitz, Alexander R., Andrew Zambanini, Margaret O. Sowell, et al.. (2008). A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short‐term, double‐blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiology and Drug Safety. 17(8). 769–781. 34 indexed citations

Haffner, S M, Steven E. Kahn, B. Zinman, et al.. (2007). Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain. Diabetologia. 50. 2 indexed citations

Kahn, Steven E., Steven M. Haffner, Mark Heise, et al.. (2006). Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine. 355(23). 2427–2443. 2202 indexed citations breakdown →

Bakris, George L., Luís M. Ruilope, Stephen McMorn, et al.. (2006). Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension. 24(10). 2047–2055. 85 indexed citations

10.

Viberti, Giancarlo, John M. Lachin, Rury R. Holman, et al.. (2006). A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic Medicine. 23(12). 1289–1294. 35 indexed citations

11.

Rosenstock, Julio, B. J. Goldstein, A Vinik, et al.. (2005). Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obesity and Metabolism. 8(1). 49–57. 52 indexed citations

12.

Bennett, S. M. A., Ajai Agrawal, Mark Heise, et al.. (2004). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetic Medicine. 21(5). 415–422. 58 indexed citations

13.

Zinman, Bernard, Steven E. Kahn, Steven M. Haffner, et al.. (2004). Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe. Diabetes. 53(12). 3193–3200. 143 indexed citations

14.

Viberti, Gian Carlo, et al.. (2003). Prevalence of microalbuminuria in recently diagnosed Type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study. Diabetologia. 46. 1 indexed citations

15.

Bakris, George L., Giancarlo Viberti, Wayde M. Weston, et al.. (2003). Rosiglitazone reduces urinary albumin excretion in type II diabetes. Journal of Human Hypertension. 17(1). 7–12. 201 indexed citations

16.

Holman, Rury R., et al.. (2003). Levels of beta-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study. Diabetologia. 46. 1 indexed citations

17.

Rosenstock, Julio, et al.. (2000). Efficacy and safety of rosiglitazone combined with glibenclamide is effective and well tolerated in type 2 diabetes patients inadequately controlled on maximum-dose glibenclamide. Diabetes Research and Clinical Practice. 50. 61–61. 8 indexed citations

18.

Heise, Mark, et al.. (2000). Rosiglitazone in combination with glibenclamide: Effect on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetes Research and Clinical Practice. 50. 64–64. 29 indexed citations

19.

Thompson, Gary A., John V. St. Peter, Mark Heise, et al.. (1996). Assessment of Doxylamine Influence on Mixed Function Oxidase Activity upon Multiple Dose Oral Administration to Normal Volunteers. Journal of Pharmaceutical Sciences. 85(11). 1242–1247. 5 indexed citations

20.

Skare, Julie A., Vincent A. Murphy, Gary A. Thompson, et al.. (1995). Safety Assessment of OTC Drugs: Doxylamine Succinate. Archives of toxicology. Supplement. 17. 326–340. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact